MCID: TST004
MIFTS: 36

Testicular Lymphoma

Categories: Cancer diseases, Reproductive diseases, Immune diseases

Aliases & Classifications for Testicular Lymphoma

MalaCards integrated aliases for Testicular Lymphoma:

Name: Testicular Lymphoma 38 12 14
Malignant Lymphoma of Testis 12 69
Lymphoma of the Testis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12253
NCIt 47 C6810
SNOMED-CT 64 277664004
UMLS 69 C0349644

Summaries for Testicular Lymphoma

MalaCards based summary : Testicular Lymphoma, also known as malignant lymphoma of testis, is related to lymphoma and primary malignant melanoma of the cervix. An important gene associated with Testicular Lymphoma is MYD88 (Myeloid Differentiation Primary Response 88), and among its related pathways/superpathways are NF-kappaB Signaling and B Cell Development Pathways. The drugs Levofloxacin and Ofloxacin have been mentioned in the context of this disorder. Affiliated tissues include testis, b cells and bone.

Related Diseases for Testicular Lymphoma

Graphical network of the top 20 diseases related to Testicular Lymphoma:



Diseases related to Testicular Lymphoma

Symptoms & Phenotypes for Testicular Lymphoma

Drugs & Therapeutics for Testicular Lymphoma

Drugs for Testicular Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 150)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
2
Ofloxacin Approved Phase 3 82419-36-1 4583
3
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
4
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
5
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
6
Cytarabine Approved, Investigational Phase 3,Phase 2 147-94-4 6253
7
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
8
Prednisone Approved, Vet_approved Phase 3,Phase 1,Phase 2 53-03-2 5865
9
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
10
Asparaginase Approved Phase 3 9015-68-3
11
Cortisone acetate Approved Phase 3 1950-04-4, 50-04-4 5745
12
Daunorubicin Approved Phase 3 20830-81-3 30323
13
Levoleucovorin Approved Phase 3 68538-85-2
14
Pegaspargase Approved, Investigational Phase 3 130167-69-0
15
Thioguanine Approved Phase 3 154-42-7 2723601
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
17
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
18
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
19 Antirheumatic Agents Phase 3,Phase 1,Phase 2,Early Phase 1
20 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
21 Anti-Infective Agents Phase 3,Phase 2,Phase 1
22 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
23 Cytochrome P-450 Enzyme Inhibitors Phase 3
24 Renal Agents Phase 3
25 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
26 Alkylating Agents Phase 3,Phase 1,Phase 2,Early Phase 1
27 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
28 Antiemetics Phase 3,Phase 2
29 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
30 Antimetabolites Phase 3,Phase 2,Phase 1
31 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
32 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
33 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Early Phase 1
34 Antiviral Agents Phase 3,Phase 2,Phase 1
35 Autonomic Agents Phase 3,Phase 2
36 BB 1101 Phase 3,Phase 2
37 Dermatologic Agents Phase 3,Phase 2,Phase 1
38 Dexamethasone acetate Phase 3,Phase 2 1177-87-3
39 Folic Acid Antagonists Phase 3,Phase 2
40 Gastrointestinal Agents Phase 3,Phase 2
41 glucocorticoids Phase 3,Phase 2,Phase 1
42 HIV Protease Inhibitors Phase 3,Phase 2
43 Hormone Antagonists Phase 3,Phase 2,Phase 1
44 Hormones Phase 3,Phase 2,Phase 1
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
46 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
47 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
48 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
49
protease inhibitors Phase 3,Phase 2
50 Protective Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 73)

id Name Status NCT ID Phase Drugs
1 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
2 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Active, not recruiting NCT00408005 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
3 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
4 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
5 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
6 Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma Completed NCT00054639 Phase 2
7 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
8 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
9 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
10 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
11 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
12 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
13 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
14 Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma Completed NCT00210379 Phase 2 rituximab;CHOP;intrathecal methotrexate
15 Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors Completed NCT00004157 Phase 2
16 Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
17 Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer Completed NCT00003408 Phase 2
18 Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation Completed NCT00003887 Phase 2
19 A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) Recruiting NCT02857426 Phase 2 Nivolumab
20 Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis Recruiting NCT00945724 Phase 2 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate
21 Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas Recruiting NCT02213913 Phase 1, Phase 2 lenalidomide;etoposide;prednisone;vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide
22 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Recruiting NCT01839916 Phase 2
23 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
24 Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Recruiting NCT01609816 Phase 1, Phase 2 Dasatinib
25 Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies Recruiting NCT01643603 Phase 1, Phase 2 Dasatinib
26 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Active, not recruiting NCT00867529 Phase 2
27 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Active, not recruiting NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
28 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Active, not recruiting NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
29 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
30 Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL Not yet recruiting NCT03212807 Phase 2 Durvalumab;Lenalidomide
31 MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma Terminated NCT00089076 Phase 1, Phase 2
32 Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer Terminated NCT01769222 Phase 1, Phase 2
33 Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma Terminated NCT00088881 Phase 2 prednisone;cyclophosphamide;doxorubicin;vincristine
34 Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant Terminated NCT01419795 Phase 2 lenalidomide
35 Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma Withdrawn NCT02281279 Phase 1, Phase 2 lenalidomide;romidepsin
36 Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies Withdrawn NCT01652014 Phase 2 cyclophosphamide;fludarabine phosphate;mycophenolate mofetil;tacrolimus
37 Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma Completed NCT00720135 Phase 1
38 Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery Completed NCT00608361 Phase 1 Dasatinib
39 Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma Completed NCT00458731 Phase 1 cediranib maleate
40 MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma Completed NCT01748721 Phase 1
41 Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers Completed NCT01254578 Phase 1 Lenalidomide
42 Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies Completed NCT01658319 Phase 1 fludarabine phosphate;methoxyamine
43 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Completed NCT00890747 Phase 1 sunitinib malate
44 Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma Completed NCT00001270 Phase 1 interleukin-1
45 Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00082823 Phase 1
46 Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00083213 Phase 1
47 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
48 Phase I Study of Weekly Oral VP-16 for AIDS-Associated Kaposi's Sarcoma Completed NCT00000660 Phase 1 Etoposide
49 Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors Completed NCT00003107 Phase 1
50 Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Recruiting NCT01366144 Phase 1 Carboplatin;Paclitaxel;Veliparib

Search NIH Clinical Center for Testicular Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Testicular Lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Testicular Lymphoma:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Testicular Lymphoma:
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Testicular Lymphoma

Anatomical Context for Testicular Lymphoma

MalaCards organs/tissues related to Testicular Lymphoma:

39
Testis, B Cells, Bone, Bone Marrow, T Cells, Liver, Colon

Publications for Testicular Lymphoma

Articles related to Testicular Lymphoma:

(show top 50) (show all 93)
id Title Authors Year
1
PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. ( 28356247 )
2017
2
Efficacy of prophylactic irradiation to the contralateral testis for patients with advanced-stage primary testicular lymphoma: an analysis of outcomes at a single institution. ( 28612278 )
2017
3
High-dose chemotherapy with autologous stem cell transplantation following systemic chemotherapy, prophylactic intrathecal methotrexate, and radiotherapy prevents relapse and improves the outcome of advanced stage primary testicular lymphoma even with cardiac involvement. ( 28883219 )
2017
4
Bilateral hydrocele. Uncommon clinical presentation of primary testicular lymphoma in the elderly. ( 28383626 )
2017
5
Straight Vessel Pattern and Rapid Filling Time: Characteristic Findings on Contrast-Enhanced Sonography of Testicular Lymphoma. ( 27335443 )
2016
6
Primary testicular lymphoma: Two case reports and review of the literature. ( 26766810 )
2015
7
Unusual continuous intra-abdominal spread of primary testicular lymphoma along the spermatic cord and gonadal vessels: Report of 2 cases. ( 26649126 )
2015
8
Primary testicular lymphoma. ( 25444963 )
2015
9
Various neurological symptoms by neurolymphomatosis as the initial presentation of primary testicular lymphoma. ( 26034480 )
2015
10
Grayscale and color Doppler features of testicular lymphoma. ( 26014335 )
2015
11
Primary testicular lymphoma: a single centre experience. ( 26422109 )
2015
12
Primary testicular lymphoma with solitary cutaneous nodule as the initial presentation. ( 26664513 )
2015
13
High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses. ( 26388135 )
2015
14
Recurrent genomic rearrangements in primary testicular lymphoma. ( 25712539 )
2015
15
Primary testicular lymphoma. ( 26433344 )
2015
16
Isolated Central Nervous System Relapse After 10A Years in a Case of Primary Testicular Lymphoma Detected on (18)F-FDG PET/CT. ( 26550055 )
2015
17
Primary testicular lymphoma. ( 24282217 )
2014
18
Bilateral primary testicular lymphoma. ( 24692378 )
2014
19
Single-center experience in the treatment of primary testicular lymphoma. ( 24853782 )
2014
20
Primary testicular lymphoma with subcutaneous masses as the sole manifestation of the first relapse and central nervous system lymphoma as the second relapse: A case report and literature review. ( 24932252 )
2014
21
Scrotal irradiation in primary testicular lymphoma: review of the literature and in silico planning comparative study. ( 22836054 )
2013
22
Clinical Features of Testicular Lymphoma. ( 24247653 )
2013
23
Primary testicular lymphoma: experience with 13 cases and literature review. ( 23355262 )
2013
24
Primary testicular lymphoma with rupture: An unusual presentation. ( 23633871 )
2013
25
Huge testicular lymphoma on 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography-computed tomography. ( 23187303 )
2013
26
F18 FDG positron emission tomography revelation of primary testicular lymphoma with concurrent multiple extra nodal involvement. ( 24019676 )
2013
27
Intraocular (vitreoretinal) lymphoma following primary testicular lymphoma. ( 23931497 )
2013
28
Testicular lymphoma. ( 23945480 )
2013
29
Three prognostic factors influence clinical outcomes of primary testicular lymphoma. ( 22965883 )
2013
30
Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma. ( 23680437 )
2013
31
FDG PET/CT of bilateral testicular lymphoma. ( 22157041 )
2012
32
Primary diffuse large B-cell testicular lymphoma: magnetic resonance imaging findings. ( 21988565 )
2012
33
Primary testicular lymphoma. ( 22424983 )
2012
34
Primary testicular lymphoma with cardiac involvement in an immunocompetent patient: case report and a concise review of literature. ( 23087799 )
2012
35
Clinics in diagnostic imaging (134). Testicular lymphoma. ( 21451930 )
2011
36
Relapsed testicular lymphoma presenting with cranial nerve neurolymphomatosis. ( 21502608 )
2011
37
Primary testicular lymphoma: the site matters. ( 20497004 )
2010
38
Primary testicular lymphoma. ( 20872294 )
2010
39
Testicular lymphoma, intraocular (vitreoretinal) lymphoma, and brain lymphoma: involvement of three immunoprivileged sites in one patient. ( 20658596 )
2010
40
Primary testicular lymphoma: a strictly homogeneous hematological disease? ( 20372839 )
2010
41
Testicular lymphoma. ( 21167372 )
2010
42
Rituximab and dose-dense chemotherapy in primary testicular lymphoma. ( 19858059 )
2009
43
Primary testicular lymphoma involving the spermatic cord and gonadal vein. ( 19300051 )
2009
44
Primary testicular lymphoma with extranodal involvement. ( 19736380 )
2009
45
Intraocular lymphoma following a primary testicular lymphoma in remission for 10 years. ( 17985076 )
2008
46
Primary testicular lymphoma. ( 17962036 )
2008
47
Testicular lymphoma: an update for clinicians. ( 18854677 )
2008
48
Primary testicular lymphoma. ( 18020104 )
2007
49
Testicular lymphoma: a case report. ( 18159836 )
2007
50
Consideration of aggressive therapeutic strategies for primary testicular lymphoma. ( 17563078 )
2007

Variations for Testicular Lymphoma

Expression for Testicular Lymphoma

Search GEO for disease gene expression data for Testicular Lymphoma.

Pathways for Testicular Lymphoma

Pathways related to Testicular Lymphoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.29 BCL6 MYD88 PTPRC
2 10.68 BCL6 PTPRC

GO Terms for Testicular Lymphoma

Biological processes related to Testicular Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription, DNA-templated GO:0045892 9.54 BCL6 FOXP1 RFX3
2 positive regulation of smooth muscle cell proliferation GO:0048661 9.32 FOXP1 MYD88
3 positive regulation of B cell proliferation GO:0030890 9.26 BCL6 PTPRC
4 negative regulation of B cell apoptotic process GO:0002903 9.16 BCL6 FOXP1
5 regulation of tumor necrosis factor production GO:0032680 8.96 FOXP1 MYD88
6 regulation of inflammatory response GO:0050727 8.8 BCL6 FOXP1 MYD88

Molecular functions related to Testicular Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.33 BCL6 FOXP1 RFX3
2 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding GO:0003705 8.65 RFX3
3 protein self-association GO:0043621 8.62 FOXP1 MYD88

Sources for Testicular Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....